The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

The Journal of Clinical Investigation
R B KimG R Wilkinson

Abstract

Currently available HIV-1 protease inhibitors are potent agents in the therapy of HIV-1 infection. However, limited oral absorption and variable tissue distribution, both of which are largely unexplained, complicate their use. We tested the hypothesis that P-glycoprotein is an important transporter for these agents. We studied the vectorial transport characteristics of indinavir, nelfinavir, and saquinavir in vitro using the model P-glycoprotein expressing cell lines L-MDR1 and Caco-2 cells, and in vivo after intravenous and oral administration of these agents to mice with a disrupted mdr1a gene. All three compounds were found to be transported by P-glycoprotein in vitro. After oral administration, plasma concentrations were elevated 2-5-fold in mdr1a (-/-) mice and with intravenous administration, brain concentrations were elevated 7-36-fold. These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain. This raises the possibility that higher HIV-1 protease inhibitor concentrations may be obtained by targeted pharmacologic inhibition of P-glycoprotein transport activity.

References

Nov 1, 1992·The Journal of Clinical Investigation·J C KolarsP B Watkins
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A T FojoI Pastan
Jan 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C Cordon-CardoJ R Bertino
Oct 9, 1995·International Journal of Cancer. Journal International Du Cancer·A D Didier, F Loor
Jan 1, 1994·Advances in Neuroimmunology·C A WileyC L Achim
Jan 1, 1993·Annual Review of Biochemistry·M M Gottesman, I Pastan
May 1, 1994·Journal of Neuropathology and Experimental Neurology·C L AchimC A Wiley
Jul 10, 1996·JAMA : the Journal of the American Medical Association·C C CarpenterP A Volberding
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M Ford
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D R FerryD J Kerr
Nov 1, 1996·Toxicology and Applied Pharmacology·L J Bain, G A LeBlanc
Jan 8, 1997·JAMA : the Journal of the American Medical Association·S G DeeksJ O Kahn
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·A SparreboomO van Tellingen

❮ Previous
Next ❯

Citations

Mar 31, 1999·Journal of Biochemical and Molecular Toxicology·E G Schuetz, A H Schinkel
Mar 1, 2002·Bulletin of Mathematical Biology·Duncan S Callaway, Alan S Perelson
May 19, 2005·Naunyn-Schmiedeberg's Archives of Pharmacology·Iouri BachmakovMartin F Fromm
Mar 15, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Ernst Petzinger, Joachim Geyer
Sep 4, 2009·European Journal of Clinical Pharmacology·Bradley L Urquhart, Richard B Kim
Sep 26, 2009·European Journal of Clinical Pharmacology·Todd HulganUNKNOWN AIDS Clinical Trials Group Study A5138 Team
Mar 24, 2010·Cancer Chemotherapy and Pharmacology·Lijuan LiuHonghao Zhou
Jun 20, 2006·European Archives of Psychiatry and Clinical Neuroscience·Norbert Thuerauf, Martin Friedrich Fromm
Mar 24, 2005·Pharmaceutical Research·Candace L GraffGary M Pollack
Jun 30, 2012·Pharmaceutical Research·Christel A S BergströmJoseph A Nicolazzo
Jun 26, 2013·Pharmaceutical Research·Noora SjöstedtMarjo Yliperttula
Aug 10, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Xiqian LanTsuneya Ikezu
Aug 11, 2005·Current HIV/AIDS Reports·Linda M CatanzaroGene D Morse
Apr 13, 2006·Current HIV/AIDS Reports·David W Haas
Jun 6, 2007·Current HIV/AIDS Reports·David R BangsbergSteven G Deeks
Dec 18, 2012·Current HIV/AIDS Reports·Marta MassanellaJulià Blanco
Nov 30, 2000·Current Infectious Disease Reports·G D Morse
Dec 6, 2011·Archives of Pharmacal Research·Hyo-Kyung Han
Nov 20, 2012·CNS Drugs·Christine EisfeldIngo Husstedt
Oct 31, 2013·CNS Drugs·William Klugh KennedyEric C Kutscher
Jan 7, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Lauretta M S ChanBarry H Hirst
Jun 1, 2005·The Medical Clinics of North America·Victoria A Cargill, Valerie E Stone
Nov 14, 2000·The American Journal of Pathology·M F FrommD Schrenk
Mar 29, 2003·Toxicology and Applied Pharmacology·Nilufer M TampalGabriele Ludewig
Oct 14, 2003·Toxicology and Applied Pharmacology·Wei ZhengJean-Francois Ghersi-Egea
Oct 16, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·L Z BenetV J Wacher
Sep 29, 2001·Advanced Drug Delivery Reviews·L Z Benet, C L Cummins
Oct 31, 2002·Advanced Drug Delivery Reviews·Martin F Fromm
Jan 22, 2003·Advanced Drug Delivery Reviews·Yan ZhangDonald W Miller
Jan 22, 2003·Advanced Drug Delivery Reviews·Jiunn H Lin
Jan 22, 2003·Advanced Drug Delivery Reviews·Haiying SunWilliam F Elmquist
Jan 22, 2003·Advanced Drug Delivery Reviews·Anne H DantzigMichael Burgess
Jun 6, 2000·Advanced Drug Delivery Reviews·A H Schinkel
Jun 6, 2000·Advanced Drug Delivery Reviews·J H Lin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.